Used in the treatment of advanced solid tumors, particularly in patients with ROS1 and TRK gene fusions. It functions as a potent inhibitor of ROS1, TRKA/B/C, and ALK kinases, helping to block signaling pathways that drive tumor growth. Demonstrates activity against tumor cells that have developed resistance to earlier generation inhibitors, making it valuable in refractory cases. Currently under investigation in clinical trials for non-small cell lung cancer and other malignancies harboring relevant genetic alterations.